Nehal S. Parikh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nehal S. Parikh has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Bee-Chun Sun
Biologics Discovery, Zai Lab (US) LLC, Menlo Park, California
19 shared publications - David I. Bellovin
Biologics Discovery, Zai Lab (US) LLC, Menlo Park, California
19 shared publications - Haoyu Zhang
WuXi AppTec, Shanghai, P.R. China
19 shared publications - Kevin X. Chen
WuXi AppTec, Shanghai, P.R. China
19 shared publications - Neil E. Bhola
Biologics Discovery, Zai Lab (US) LLC, Menlo Park, California
19 shared publications - O. Petter Veiby
Biologics Discovery, Zai Lab (US) LLC, Menlo Park, California
19 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Hematology
- Vol. 2026 (1) , 5825111
A Rare Case of Neonatal Kaposiform Hemangioendothelioma With Kasabach–Merritt Phenomenon Presenting as an Abdominal Mass Without Cutaneous Manifestations
Kaposiform hemangioendothelioma (KHE) is a rare vascular neoplasm that typically presents in infancy or early childhood, classified as a locally aggressive/borderline vascular tumor. It most commonly involves superficial and deep soft tissues, often demonstrating infiltrative growth into adjacent muscle and bone, whereas retroperitoneal or intraabdominal presentations are less frequent. KHE is frequently complicated by Kasabach–Merritt phenomenon (KMP), a severe consumptive coagulopathy characterized by profound thrombocytopenia, microangiopathic hemolytic anemia, and hypofibrinogenemia with life‐threatening sequelae. We report a case of a male neonate who developed KMP secondary to an abdominal KHE without overlying cutaneous involvement. Diagnosis was established through integration of clinical features, imaging findings, hematological evaluation, and confirmatory biopsy. This patient was managed with a multimodal regimen of sirolimus, corticosteroids, and vincristine, resulting in significant clinical improvement. This case underscores both the diagnostic complexity and therapeutic challenges of KHE complicated by KMP, particularly when lesions occur in deep anatomical sites. Given the rarity of this condition, current management strategies rely largely on expert consensus and case‐based experience, though recent randomized trial and consensus have established sirolimus‐based regimens as highly effective first‐line therapy.
- 1 January 2026
- Published by Wiley in Case Reports in Hematology
- Vol. 2026 (1) , 5825111
Open AccessA Rare Case of Neonatal Kaposiform Hemangioendothelioma With Kasabach–Merritt Phenomenon Presenting as an Abdominal Mass Without Cutaneous Manifestations
Kaposiform hemangioendothelioma (KHE) is a rare vascular neoplasm that typically presents in infancy or early childhood, classified as a locally aggressive/borderline vascular tumor. It most commonly involves superficial and deep soft tissues, often demonstrating infiltrative growth into adjacent muscle and bone, whereas retroperitoneal or intraabdominal presentations are less frequent. KHE is frequently complicated by Kasabach–Merritt phenomenon (KMP), a severe consumptive coagulopathy characterized by profound thrombocytopenia, microangiopathic hemolytic anemia, and hypofibrinogenemia with life‐threatening sequelae. We report a case of a male neonate who developed KMP secondary to an abdominal KHE without overlying cutaneous involvement. Diagnosis was established through integration of clinical features, imaging findings, hematological evaluation, and confirmatory biopsy. This patient was managed with a multimodal regimen of sirolimus, corticosteroids, and vincristine, resulting in significant clinical improvement. This case underscores both the diagnostic complexity and therapeutic challenges of KHE complicated by KMP, particularly when lesions occur in deep anatomical sites. Given the rarity of this condition, current management strategies rely largely on expert consensus and case‐based experience, though recent randomized trial and consensus have established sirolimus‐based regimens as highly effective first‐line therapy.
- Open Access
- 1 September 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 3 (9) , 1731-1742
Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor
DNA-dependent protein kinase (DNA-PK), a driver of the non-homologous end-joining (NHEJ) DNA damage response pathway, plays an instrumental role in repairing double-strand breaks (DSB) induced by DNA-damaging poisons. We evaluate ZL-2201, an orally bioavailable, highly potent, and selective pharmacologic inhibitor of DNA-PK activity, for the treatment of human cancerous malignancies. ZL-2201 demonstrated greater selectivity for DNA-PK and effectively inhibited DNA-PK autophosphorylation in a concentration- and time-dependent manner. Initial data suggested a potential correlation between ataxia-telangiectasia mutated (ATM) deficiency and ZL-2201 sensitivity. More so, ZL-2201 showed strong synergy with topoisomerase II inhibitors independent of ATM status in vitro. In vivo oral administration of ZL-2201 demonstrated dose-dependent antitumor activity in the NCI-H1703 xenograft model and significantly enhanced the activity of approved DNA-damaging agents in A549 and FaDu models. From a phosphoproteomic mass spectrometry screen, we identified and validated that ZL-2201 and PRKDC siRNA decreased Ser108 phosphorylation of MCM2, a key DNA replication factor. Collectively, we have characterized a potent and selective DNA-PK inhibitor with promising monotherapy and combinatory therapeutic potential with approved DNA-damaging agents. More importantly, we identified phospho-MCM2 (Ser108) as a potential proximal biomarker of DNA-PK inhibition that warrants further preclinical and clinical evaluation. Significance: ZL-2201, a potent and selective DNA-PK inhibitor, can target tumor models in combination with DNA DSB-inducing agents such as radiation or doxorubicin, with potential to improve recurrent therapies in the clinic.
- 1 September 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 3 (9) , 1731-1742
Open AccessDiscovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor
DNA-dependent protein kinase (DNA-PK), a driver of the non-homologous end-joining (NHEJ) DNA damage response pathway, plays an instrumental role in repairing double-strand breaks (DSB) induced by DNA-damaging poisons. We evaluate ZL-2201, an orally bioavailable, highly potent, and selective pharmacologic inhibitor of DNA-PK activity, for the treatment of human cancerous malignancies. ZL-2201 demonstrated greater selectivity for DNA-PK and effectively inhibited DNA-PK autophosphorylation in a concentration- and time-dependent manner. Initial data suggested a potential correlation between ataxia-telangiectasia mutated (ATM) deficiency and ZL-2201 sensitivity. More so, ZL-2201 showed strong synergy with topoisomerase II inhibitors independent of ATM status in vitro. In vivo oral administration of ZL-2201 demonstrated dose-dependent antitumor activity in the NCI-H1703 xenograft model and significantly enhanced the activity of approved DNA-damaging agents in A549 and FaDu models. From a phosphoproteomic mass spectrometry screen, we identified and validated that ZL-2201 and PRKDC siRNA decreased Ser108 phosphorylation of MCM2, a key DNA replication factor. Collectively, we have characterized a potent and selective DNA-PK inhibitor with promising monotherapy and combinatory therapeutic potential with approved DNA-damaging agents. More importantly, we identified phospho-MCM2 (Ser108) as a potential proximal biomarker of DNA-PK inhibition that warrants further preclinical and clinical evaluation. Significance: ZL-2201, a potent and selective DNA-PK inhibitor, can target tumor models in combination with DNA DSB-inducing agents such as radiation or doxorubicin, with potential to improve recurrent therapies in the clinic.
- Open Access
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 treatment exhibits potent antitumor efficacy in vivo.
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 treatment exhibits potent antitumor efficacy in vivo.
- Open Access
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
Phenotypic effects of combining ZL-2201 and Doxorubicin
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
Phenotypic effects of combining ZL-2201 and Doxorubicin
- Open Access
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 anti-proliferative IC50s and ATM mutational and VAF status
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 anti-proliferative IC50s and ATM mutational and VAF status
- Open Access
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S6 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 reduces DNA damage-induced MCM2 phosphorylation (Ser108).
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 reduces DNA damage-induced MCM2 phosphorylation (Ser108).
- Open Access
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 anti-proliferative IC50s and ATM mutational and VAF status
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
ZL-2201 anti-proliferative IC50s and ATM mutational and VAF status
- Open Access
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
Kinetics of Bleomycin-induced DNA-PK phosphorylation by ZL-2201
- 9 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
Kinetics of Bleomycin-induced DNA-PK phosphorylation by ZL-2201